<DOC>
	<DOCNO>NCT00493649</DOCNO>
	<brief_summary>The purpose research study find effect ( good bad ) docetaxel/cyclophosphamide ( brand name : Taxotere Cytoxan , TC ) plus trastuzumab ( brand name : Herceptin , H ) HER2+ breast cancer .</brief_summary>
	<brief_title>Adj TC + Herceptin Early Stage Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>A woman eligible inclusion study meet follow criterion : Has HER2+ ( IHC stain 3+ [ uniform , intense membrane stain &gt; 30 % invasive tumor cell ] , FISH result .6 HER2 gene copy per nucleus FISH ratio [ HER2 gene signal chromosome 17 signal ] &gt; 2.2 ; patient equivocal FISH ratio result 1.82.2 also eligible 3+ IHC ) ( Appendix IX ) ; Stage I , IIA , IIB , IIIA T13N13M0 disease . At discretion Treating Physician , patient 4+ node factor patient choice , old age , preexist cardiac disease normal MUGA ECHO may enrol separate subgroup . Has operable , histologically confirm , invasive carcinoma breast . Has know ER PR status Has adequate tumor specimen available FISH analysis TOP2A status ( See Appendix VII ) Has prior chemotherapy unless give &gt; 5 year ago breast cancer cancer Has ECOG Performance Status ( PS ) 01 Age &gt; 18 &lt; 70 year old . Has laboratory value : See protocol specific detail Has aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) alkaline phosphatase ( ALP ) within range show . In determine eligibility abnormal 2 value ( AST ALT ) use . See protocol specific detail Has complete surgical resection primary breast tumor : either lumpectomy mastectomy sentinel lymph node axillary dissection . It &lt; 84 day since date definitive surgery , adequate wound heal determine Treating Physician Has evidence metastatic disease physical examination xray ; appropriate scan need individual patient ( eg , bone scan ; abdominal , chest CT ; PET PET/CT ; ultrasound ; MRI indicate evidence metastatic disease . Has normal cardiac function evidence LVEF &gt; 50 % , must within normal limit ( WNL ) institutional standard , determine multiple gated acquisition ( MUGA ) scan . An echocardiogram ( ECHO ) . The modality must use throughout study evaluate LVEF . Ejection fraction ( EF ) determine ECHO must WNL institutional standard . Has negative serum pregnancy test within 7 calendar day prior registration ( female patient childbearing potential [ surgically sterilize menarche 1 year postmenopause ] ) . If fertile , patient agree use acceptable method birth control ( barrier contraceptive ) avoid pregnancy duration study period 3 month thereafter Has sign Patient Informed Consent Form Has sign Patient Authorization Form A woman exclude study meet follow criterion : Has evidence disease follow complete surgical resection primary tumor metastatic workup Has Stage IIIB breast cancer ( T4 disease ; ie , patient fix tumor , peau d'orange skin change , skin ulceration , inflammatory change ) . Has Stage IV breast cancer ( M1 disease TNM stag system ) Had prior chemotherapy breast cancer cancer within last 5 year ( neoadjuvant chemotherapy study permit ) Has history severe hypersensitivity reaction drug formulate polysorbate 80 Has myocardial infarction ( MI ) within 6 month trial enrollment , New York Heart Association ( NYHA ) Class II great heart failure ( see Appendix III ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , clinically significant pericardial disease , electrocardiographic evidence acute ischemic change Has abnormal baseline MUGA ( ECHO ) ( &lt; 50 % , less institutional LLN ) Is receive concurrent immunotherapy , hormonal therapy , radiation therapy . Adjuvant hormonal therapy , need , may give radiation therapy treatment trastuzumab completion chemotherapy . Is receive concurrent investigational therapy receive therapy within past 30 calendar day Has peripheral neuropathy &gt; Grade 1 Has serious uncontrolled intercurrent medical psychiatric illness , include serious viral ( include clinically define AIDS ) , bacterial fungal infection ; history uncontrolled seizure , diabetes , CNS disorder deem Treating Physician clinically significant , preclude inform consent Has active hepatitis B hepatitis C abnormal liver function test ( LFTs ) know HIV positive Has history malignancy within last 5 year ( except cure basal cell carcinoma skin carcinoma situ uterine cervix ) , could affect diagnosis assessment study drug Is obese patient Treating Physician would comfortable administer full dos study drug calculate BSA . Obese patient treat base actual body weight . Obese patient treat full dos base actual BSA eligible Is pregnant breastfeed woman Is deem unable comply requirement study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>